Semaglutide vs Sitagliptin

NCT05195944 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial compares the effects of semaglutide and sitagliptin on blood sugar control in adults with diabetes who have had a liver transplant or have liver conditions like NASH or NAFLD.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 58 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2022-10 · est. completion 2026-12

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT05195944 ↗

Description as written by the study sponsor.

The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled Diabetes Mellitus.

Treatments tested

Semaglutide Treatment Drug

The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one "sitagliptin placebo" tablet per day.
Sitagliptin 100mg Drug

participants will take 100mg tablet of Sitagliptin once daily, along with a "semaglutide placebo" pill for the duration of the 26 week treatment period

Main thing measured	Change in HbA1c level
Sponsor	University Health Network, Toronto
Conditions studied	Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05195944 ↗